Alexza Pharmaceuticals has announced that its European partner Ferrer has launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients in Romania. Ferrer has a distribution agreement with Galenica for distribution in that country. In the US, Teva launched the product earlier this month.
Alexza President and CEO Thomas B. King said, “With the launch of Adasuve in Romania, Ferrer is continuing to execute on its planned commercial launch. We are very pleased with Ferrer’s progress in making Adasuve available in the EU. Manufacturing finished product for our commercial partners is one of Alexza’s key priorities and we continue to support the global introduction of Adasuve.”
Ferrer had already launched Adasuve in Germany and in Austria. According to Alexza, Ferrer plans to launch the product in additional European countries this year and next.
Read the Alexza press release.
